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Abstract Attention-deficit hyperactivity disorder (ADHD)
is a common behavioural disorder that affects not only
children and adolescents but also adults; however, diag-
nosis of adult ADHD is difficult because patients seem to
have reduced externalized behaviour. ADHD is a multi-
factorial disorder in which many genes, all with small
effects, are thought to cause the disorder in the presence of
unfavourable environmental conditions. Therefore, in this
pilot study, we explored the expression profile of a list of
previously established candidate genes in peripheral blood
samples from adult ADHD subjects (n = 108) and
compared these results with those of healthy controls
(n = 35). We demonstrate that combining the gene
expression levels of dopamine transporter (SLC6A3),
dopamine D5 receptor, tryptophan hydroxylase-1, and
SNAP25 as predictors in a regression model resulted in
sensitivity and specificity of over 80 % (ROC: max
R2 = 0.587, AUC = 0.917, P \ 0.001, 95 % CI: 0.900–
0.985). In conclusion, the combination of these four genes
could represent a potential method for estimating risk and
could be of diagnostic value for ADHD. Nevertheless,
further investigation in a larger independent population
including different subtypes of ADHD (inattentive,
hyperactive, or combined type) patients is required to
obtain more specific sets of biomarkers for each subtype as
well as to differentiate between child, adolescent, and
adulthood forms.
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Introduction
Attention-deficit hyperactivity disorder (ADHD) is one
of the most common behavioural disorders in child and
adolescent psychiatry (prevalence variance of 5–12 %)
(Faraone et al. 2003; Polanczyk et al. 2007), while recently
it was demonstrated in adults with a prevalence variance of
3–6 % (Klassen et al. 2010; Simon et al. 2009; Lara et al.
2009). The disorder is characterized by impaired attention,
motor hyperactivity, and increased impulsivity (Haavik
et al. 2010; American Psychiatric Association A 2000).
Adult ADHD is a well-characterized condition, although it
is generally accepted that the onset of ADHD usually
occurs in childhood (Biederman 2005; American Psychi-
atric Association A 2000). The diagnosis of and treatment
for adult ADHD can be challenging since hyperactive
symptoms and externalized behaviours tend to wane with
age, making diagnosis difficult (Klassen et al. 2010).
Despite evidence pointing towards a primarily genetic
basis for ADHD, no specific genetic variants are yet known
(Wood and Neale 2010; Banaschewski et al. 2010; Franke
et al. 2009). The candidate genes explored so far confirm
only small-to-moderate effects, with odds ratios (OR)
ranging from 1.03 to 1.83 (Faraone and Mick 2010). The
most frequently studied genes affecting the susceptibility to
ADHD are the dopamine D4 receptor (DRD4), DRD5,
dopamine transporter (SLC6A3, DAT1), 25-kDa synapto-
somal-associated protein (SNAP25), serotonin transporter
(SLC6A4, SERT), and tryptophan hydroxylase 2 (TPH2)
(Faraone and Mick 2010; Gizer et al. 2009), but all seem to
have mild effects. Additionally, environmental factors such
as stress and prenatal alcohol or nicotine consumption
could also influence the ADHD phenotype and prevalence,
which are part of many components regarded as gene 9
environmental interaction (Nigg et al. 2010). Therefore,
there is probably no single gene indicating the presence of
ADHD, but rather polygenetic markers that in combination
increase the risk of the disorder. Such an approach, using a
wide array of parameters, is referred to as biomarkers.
Biomarkers can be used as diagnostic tools to identify or
stage disease, as indicators of disease prognosis or pre-
dictors, or to monitor clinical response to therapy. As
defined by the Biomarkers Definitions Working Group, a
biomarker is ‘a characteristic that is objectively measured
and evaluated as an indicator of normal biological pro-
cesses, pathogenic processes, or pharmacologic responses
to a therapeutic intervention’ (Biomarkers Definitions
Working Group 2001). Consequently, in this pilot study,
we explore a group of candidate genes comprising the
described risk genes known in the literature (Faraone and
Mick 2010; Gizer et al. 2009), and corticotropin-releasing
factor binding protein (CRHBP) was selected as a response
to stress, which is also thought to be a risk factor for
ADHD, to assess their expression profile in peripheral
blood samples taken from adult ADHD subjects compared
with samples from healthy controls. Such concept was
previously reported in which transcriptional profiling
resulted in identification of several candidate genes in
blood and brain, especially for schizophrenic patients
(Glatt et al. 2005; Tsuang et al. 2005; Mehler-Wex et al.
2006; Noori-Daloii et al. 2010; Taurines et al. 2010) and
Alzheimer’s and Parkinson’s disease patients (Gru¨nblatt
et al. 2009, 2010; Scherzer et al. 2007).
The concept of peripheral blood cells as a ‘window’ into
the central nervous system (CNS) was proposed nearly a
decade ago (Gladkevich et al. 2004; Burczynski and
Dorner 2006), whereas CNS versus peripheral expression
has proven to moderately correlate (Sullivan et al. 2006;
Cai et al. 2010). We hypothesized that none of the bio-
markers would individually provide high sensitivity and
specificity; therefore, we used the best known candidates in
a combined gene expression analysis and a comprehensive
regression model.
Methods
Subject recruitment
Patients and controls were recruited and phenotypically
characterized by a team of experienced psychiatrists at the
outpatient units of the Department of Psychiatry, Psycho-
somatics, and Psychotherapy, University of Wu¨rzburg,
Germany, according to the DSM-IV criteria (American
Psychiatric Association A 2000; Jacob et al. 2007). The
diagnosis of childhood and youth manifestation of ADHD
was retrospectively assessed with the DSM-IV symptom
list for ADHD, which was used as a structured clinical
interview. Additional information from parents and school
report cards was included if available. Adult symptom-
atology was assessed with the DSM-IV symptom list for
ADHD. To ensure diagnostic validity, informative input
from partners, relatives, and friends was also collected.
Co-morbidity was assessed with the structured clinical
interviews of axis I (SCID I) disorders (First et al. 1997).
Exclusion criteria were autistic disorder, psychotic disor-
der, bipolar affective disorder, history of epilepsy, other
neurologic disorder, severe chronic medical condition,
IQ \ 80 (Jacob et al. 2007). Additionally, detailed infor-
mation on medication, alcohol abuse, and smoking habits
was collected. Control subjects underwent diagnostic pro-
cedures similar to those of the patients to exclude any other
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psychiatric disorders. Controls were recruited through
local newspaper ads. The subjects provided informed
consent according to the Helsinki Declaration. The study
protocol was approved by the local ethics committee of the
Universities of Wu¨rzburg, Germany. Written informed
consent was obtained from all subjects or their primary
caregivers.
One hundred and eight patients diagnosed with ADHD
(46 men and 62 women) and 35 healthy controls (19 men
and 16 women) were included in this study (Table S1,
supplemental data). All subjects were with German
ancestry that ensured a homogenous sample analysis. The
gender distribution was similar in both diagnostic groups
(P = 0.247, Table S1), whereas the mean age was signif-
icantly older in the control group (controls = 39.6 ±
9.49 years, ADHD = 34.7 ± 10.52 years; P = 0.009).
The most frequent lifetime co-morbidities were substance-
related disorders (alcohol, 11.1 %; cannabis, 22.2 %), and
other co-morbidities were present in 11.1 % of patients. In
ADHD patients, the combined subtype was diagnosed in
70.4 % (n = 76), whereas 21.3 % (n = 23) were primarily
inattentive, and 5.5 % (n = 6) were primarily hyperactive.
Whole blood was collected with the PAXgeneTM Blood
RNA system (Becton–Dickinson GmbH, Heidelberg,
Germany) and EDTA-blood tubes. Blood samples were
frozen at -20 C until further processing for total RNA
extraction, whereas fresh blood was processed immediately
for DNA isolation.
Genomic DNA extraction
DNA was prepared from 2 ml EDTA-blood using pro-
teinase K as described previously (Gru¨nblatt et al. 2005).
The DNA was then aliquoted into cryo-Vials (Nunk
GmbH, Wiesbaden, Germany) and frozen at -70 C until
processing.
Genotyping
Genotyping was conducted as previously described
for SNAP25 ?2015 (rs6077690), SNAP25 ?80609
(rs363006), SNAP25 -523 (rs6039769) (Renner et al.
2008), serotonin transporter linked polymorphic region
(HTTLPR; SLC6A4 tri allelic) (Lesch et al. 1996; Hu et al.
2005), TPH2 SNP25 (rs4570625) (Walitza et al. 2005),
SLC6A3 30UTR VNTR, and DRD4 exon 3 VNTR (Walitza
et al. 2008).
Total RNA extraction
Total RNA was prepared with the PAXgeneTM Blood RNA
Kit 50 (PreAnalytiX, Qiagen and BD, Germany). RNA
isolation reagents were prepared from 0.2 lM filtered,
diethyl pyrocarbonate (DEPC)-treated water (Fermentas
Inc., Hanover, MD, USA) throughout the isolation proce-
dure. Total RNA samples were spectrophotometrically
scanned (Experion, BioRad Co., Hercules, CA, USA) from
220 to 320 nm; the A260/A280 of total RNA was typically
[1.9.
Quantitative real-time RT-PCR analysis
Quantitative real-time RT-PCR was used for the following
7 genes (Table S2, supplemental data): SLC6A3, DRD4,
DRD5, TPH1 (variant 1 was tested in the peripheral sam-
ples since variant 2 [TPH2] is not expressed in the
peripheral blood but only in the CNS), SLC6A4, SNAP25,
CRHBP; additionally, 6 reference genes were used as
internal controls. Total RNA (500 ng) from each sample
was reverse transcribed with the random hexamer and
oligo-dT primer mix using iScript (BioRad Co., Hercules,
CA, USA). Quantitative real-time PCR was performed in
the iCycler iQ system (BioRad Co., Hercules, CA, USA) as
described previously (Gru¨nblatt et al. 2009). Real-time
PCR was subjected to thermocycler amplification as
described previously (Gru¨nblatt et al. 2009). All PCR
reactions were run in duplicate. The amplified transcripts
were quantified using the comparative CT method analysed
with the BioRad iCycler iQ system program. Gene
expression levels were normalized to the 6 reference genes
according to GeNorm (Vandesompele et al. 2002). Data
were analysed with Microsoft Excel 2000 to generate raw
expression values.
Statistical analysis
Because of non-normal data distribution, parametric
procedures including all potential moderating variables
could not be employed; therefore, we tried to control for
the influence of age on individual mRNA levels by
looking at the correlation between age and gene expres-
sion. The relationship between genotype, diagnosis, and
gender was explored with a chi-squared test on 2 (diag-
nosis) 9 3 (genotype) cross-tabs both with gender as a
layer variable for each gene and for both genders com-
bined. For analysis of our main variable of interest—gene
expression differences between diagnostic groups—non-
parametric Mann–Whitney U tests for differences in
mean rank between ADHD subjects and controls were
performed. For those genes returning significant main
effects of diagnosis, we also checked for the influence of
genotype on gene expression within each diagnostic
group.
Assuming a combination of markers would yield the
best prediction, we employed binary logistic regression to
first assess the diagnostic utility of the expression of our
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candidate genes for the ability to differentiate between
ADHD patients and healthy controls. To that end, we
entered those genes showing differential expression
between ADHD and controls as well as the potentially
confounding variables age and gender into the model. We
applied a filter, excluding cases rated as outliers on any one
of the respective RNA levels. Outliers were identified using
box plots, with values more than 1.5 and 2 box-lengths
away from the box ends are characterized as such. In total,
19 samples had to be excluded, because they were classi-
fied as outliers on the expression level of at least one gene.
The predicted probabilities from significant predictors from
this whole model were then ultimately used for building a
receiver operating characteristic (ROC) curve and assess-
ing sensitivity and specificity. Since odds ratios (OR) were
extremely large due to the small unit of the detected gene
expression levels (e.g. 6666.13 for TPH1), the original
mRNA values were multiplied by a factor of 100. Signif-
icances remained unchanged by this procedure. The sig-
nificance level was set as 0.05 (nominal P values). All
computations were completed using the statistical com-
puting environment, PASW Statistics 18.
Results
All genotypes were in Hardy–Weinberg equilibrium. For
exact genotype distributions, see supplementary Table S3.
From the results of the different genotypes, we detected no
association between ADHD and any of the polymorphisms.
Except for lower TPH1 levels (r = -0.174, P = 0.039)
being weakly associated with older age, no significant
correlations between age and any of the genes were
observed (all P [ 0.105; for details, see supplementary
data, Tables S4 and S5).
The dopaminergic system showed the most prominent
differences between ADHD patients and controls, with
patients having elevated SLC6A3 expression (P = 0.001),
and both DRD4 and DRD5 showed higher expression
levels in ADHD patients compared with controls
(P = 0.005 and P \ 0.001, respectively; Table 1; supple-
mentary Figure S1). Furthermore, there was a notable
increase in SNAP25 in samples from ADHD subjects
compared with controls (P = 0.01). With regard to the
serotonergic genes, no difference was found for SLC6A4
(P = 0.696); however, ADHD subjects had higher
expression of the rate-limiting enzyme TPH1 mRNA
(P \ 0.001). CRHBP mRNA was the only gene expressed
at lower levels in ADHD cases (P = 0.037). Within the
diagnostic groups, no influence of genotype on gene
expression was observed (Table 1; Supplementary Figure
S2).
For our first binary logistic regression model, we used a
forward stepwise approach, in which all variables were
successively entered. In this case, we used the expression
levels of all candidate genes (SLC6A3, DRD4, DRD5,
TPH1, SNAP25, and CRHBP) along with age and gender
as potential predictors. Concerning multicolinearity, all
correlations of variables within this model were below
0.510. The whole model returned the following significant
regressors: DRD5 (P = 0.011, OR = 1.40, 95 % CI:
1.08–1.81), TPH1 (P \ 0.009, OR = 1.10, 95 % CI:
1.02–1.17), and SNAP25 (P = 0.021, OR = 1.07, 95 %
CI: 1.01–1.13) and a trend-level contribution for SLC6A3
(P = 0.069, OR = 1.06, 95 % CI: 1.00–1.13) (Supple-
mentary Table S6). The receiver operating characteristic
(ROC) curve was built using these four genes (Fig. 1: max
R2 = 0.587, AUC = 0.917, P \ 0.001, 95 % CI: 0.900–
0.985). Combining gene expression levels of SLC6A3,
DRD5, TPH1, and SNAP25 as predictors in a regression
Table 1 Gene expression patterns in attention-deficit hyperactivity disorder (ADHD) patients versus control subjects and genotype effects
ADHD subjects
(mean ± SD)
Controls subjects
(mean ± SD)
P Genotype effects (P values)
ADHD Controls
SLC6A3 0.37 ± 0.19 [ 0.25 ± 0.09 0.001 0.537 0.783
DRD4 0.36 ± 0.27 [ 0.24 ± 0.14 0.005 0.684 0.206
DRD5 0.13 ± 0.09 [ 0.07 ± 0.04 \0.001 N/A N/A
CRHBP 0.17 ± 0.11 \ 0.21 ± 0.12 0.037
SNAP25 0.41 ± 0.29 [ 0.24 ± 0.08 0.001 0.311 0.126
TPH1 0.44 ± 0.30 [ 0.19 ± 0.06 \0.001 0.800 0.598
SLC6A4 0.16 ± 0.09 0.17 ± 0.09 N/S N/D N/D
N/A data not available since no genotyping was conducted, N/S not significant, N/D not done (since the main result was not significant), SLC6A3
dopamine transporter (DAT), DRD4 dopamine D4 receptor, DRD5 dopamine D6 receptor, CRHBP corticotropin-releasing factor binding protein,
SNAP25 synaptosomal-associated protein of 25 kDa, TPH1 tryptophan hydroxylase, SLC6A4 serotonin transporter
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model, 80 % of cases could be correctly classified as ADHD
subjects or controls. Any other combination with other genes
or with three or two of the above four resulted in a worse
prediction of ADHD compared with this four-gene combi-
nation. We achieved sensitivity and specificity of over 80 %
(e.g. sensitivity of 81 % and specificity of 82 % at a cut-off
of 0.69) according to the whole-model ROC analysis.
The combined approach was superior to any individual
variables predictive ability, where separate logistic models
returned the following results: SLC6A3 (AUC = 0.694,
sensitivity = 0.696, specificity = 0.645), DRD5 (AUC =
0.749, sensitivity = 0.752, specificity = 0.625), SNAP25
(AUC = 0.689, sensitivity = 0.637, specificity = 0.618),
and TPH1 (AUC = 0.812, sensitivity = 0.776, specific-
ity = 0.706) (Table 2).
Discussion
We showed that a combination of expression patterns for
four ADHD-associated genes in the peripheral blood of
adult ADHD patients could be a potential method for
estimating risk and have possible diagnostic value for
ADHD. Since ADHD is a heterogeneous disorder with a
high comorbidity rate, a complex diagnostic tool with more
than one marker was expected (Wallis 2010). We show that
a combination of expression levels of four genes, SLC6A3,
DRD5, TPH1, and SNAP25, provide relatively high sensi-
tivity and specificity, indicating the potential use of this
combination of biomarkers to identify the risk of ADHD in
adults. Three of the genes studied were unaffected by age,
whereas TPH1 showed a very mild decrease in expression
with age. Recently, in a study for mRNA alterations in
whole blood from child and adolescent ADHD compared
with autism spectrum disorder (ASD) and with controls, no
group differences were found for TPH1 mRNA expression
(Taurines et al. 2011). Still, TPH1 expression of the ADHD
group (n = 51) was slightly higher than that of the ASD
(n = 26) or the control (n = 39) group (Taurines et al.
2011), which might indicate the beginning of alterations
with age for ADHD group. As an additional parameter, we
analysed the association of the genotypes for the same
genes studied with ADHD. We observed no overall asso-
ciation between genotype and ADHD for any of the genes
tested; moreover, we checked for an additional influence of
genotype on the mRNA levels of those genes found to be
differently expressed in patients and controls; however, this
also showed no difference. Since transcript expression
seems to be influenced rather by multiple factors such as
multiple genetic polymorphism as well as environmental
factors, the notion that multiple transcript analysis would
be necessary to identify ADHD cases is pointed out.
The four candidate genes identified as the best bio-
markers in this study were previously described in other
ADHD association studies (Stergiakouli and Thapar 2010;
Gizer et al. 2009). The most consistent evidence for an
association with ADHD exists for the DRD5 gene micro-
satellite (Squassina et al. 2008) and the SLC6A3 gene
variable tandem repeat (VNTR) at the 30 UTR (Stergiakouli
and Thapar 2010; Gizer et al. 2009). In contrast, very weak
individual associations were reported for TPH1 (Gizer
et al. 2009; Johansson et al. 2010) and SNAP25 (Gizer
et al. 2009; Forero et al. 2009; Kim et al. 2007), but the 30
UTR of the latter was significant in a recent meta-analysis
(Gizer et al. 2009). Each of these genes often showed a
Fig. 1 Receiver operating characteristic (ROC) curve for the candi-
date markers, dopamine transporter (SLC6A3), dopamine D5 receptor
(DRD5), tryptophan hydroxylase 1 (TPH1), and synaptosomal-
associated protein of 25 kDa (SNAP25) mRNA
Table 2 Individual logistic regression models for each biomarker
P value OR (95 % CI) AUC
Age 0.018 0.95 (0.92–0.99) 0.646
Gender 0.229 0.63 (0.29–1.35) 0.558
SLC6A3 0.003 1.06 (1.02–1.10) 0.694
DRD4 0.015 1.04 (1.01–1.06) 0.656
DRD5 0.001 1.21 (1.08–1.35) 0.749
CRHBP 0.074 0.97 (0.94–1.00) 0.381
SNAP25 0.002 1.05 (1.02–1.08) 0.689
TPH1 \0.001 1.09 (1.05–1.14) 0.812
SLC6A4 0.705 0.99 (0.95–1.04) 0.478
AUC area under the curve (for gender 1 = male, 2 = female), OR
odds ratio, SLC6A3 dopamine transporter (DAT), DRD4 dopamine
D4 receptor, DRD5 dopamine D6 receptor, CRHBP corticotropin-
releasing factor binding protein, SNAP25 synaptosomal-associated
protein of 25 kDa, TPH1 tryptophan hydroxylase, SLC6A4 serotonin
transporter
OR higher value refers to attention-deficit hyperactivity disorder
(ADHD) cases, P \ 0.05 (uncorrected)
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very modest genetic effect on the risk of ADHD (meta-
analysis: SLC6A3 10 repeats OR = 1.1, 95 % CI:
1.03–1.17; DRD5 50 Flank OR = 1.22, 95 % CI:
1.10–1.36; TPH1 intron 6 OR = 0.99, 95 % CI: 0.89–1.10;
SNAP25 30 UTR OR = 1.15, 95 % CI: 1.01–1.31) (Gizer
et al. 2009). Interestingly, SLC6A3 seems to have an
opposite effect in persistent adult ADHD compared with
childhood ADHD (Franke et al. 2010). Therefore, the need
for sensitive biomarkers that in combination achieve a
much higher OR than the ones investigated to date is
necessary. In our study, we combined multiple genetic
markers with relatively good success, which confirms the
potential of this strategy.
A limitation of this study is the small sample size;
however, since this was planned as an exploratory study,
the sample size still pointed to the possible candidate genes
that should be than confirmed in the future. Additionally,
the different co-morbidities existing in our population
might have affected the results, which we could not control
for properly because of the limited group size. Since adult
ADHD is highly co-morbid with other ICD diagnoses
(Wallis 2010), there might be common pathways for the
array of these disorders that still provides a good diagnostic
tool. It will be necessary to look at subgroups in future
studies with a larger population and to analyse markers for
a specific diagnosis. Furthermore, a larger population
would enable us to incorporate the different pharmaco-
logical treatments to rule out any effects of these on gene
expression. The biggest limitation might be the fact that the
populations we examined and determined the test’s sensi-
tivity and specificity from were extensively evaluated by
trained professionals, and the subjects included in the study
had either a very clear-cut case of ADHD or were com-
pletely healthy. However, in real-life patients, presenta-
tions are often a lot more ambiguous, making the
development of a highly sensitive and specific test a top
priority. In that case, our markers might do less well, so
results need to be validated with a broader spectrum of
ADHD phenotypes and severities, and the predictive value
needs to be determined.
In conclusion, we demonstrate the potential of periph-
erally expressed genes as biomarkers that could be used to
diagnose ADHD. Further investigation of additional can-
didate transcripts in a larger independent population
including different ADHD sub-groups (inattentive, hyper-
active, and combined type) and comparing them not only
with healthy controls but also with other psychiatric
disorders is required to obtain more specific sets of bio-
markers for each sub-disorder and to differentiate between
childhood, adolescent, and adult forms of ADHD.
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